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Objectives: FN can be a serious complication of CHT, increasing mortality risk 
and health care costs. Incidence and inpatient hospital costs of FN in Switzerland 
are currently not reported; therefore this study aimed to: 1. Estimate the number 
of FN-related hospitalizations. 2. Assess inpatient hospital costs per FN event in 
Switzerland. MethOds: The main data source was MedStat, a comprehensive data-
base of all Swiss hospitalizations from 1997-2010. BC and NHL cases were identified 
from ICD-10-GM codes. Hospitalizations for FN were identified by a simultaneous code 
of BC or NHL and neutropenia. Incident cases of cancer were identified as patients 
treated in 2010 for the first time since 2002. Results were compared to data from the 
Foundation National Institute for Cancer Epidemiology and Registration (NICER). Cost 
data stems from the cantonal hospital of Winterthur. Results: Using MedStat data, 
645 male and 557 female NHL patients and 6’391 female BC patients were hospital-
ized in 2010 for the first time. Corresponding annual incidence data from NICER were 
780 male and 688 female NHL patients and 5’388 female BC patients. The proportion 
of hospitalizations due to FN was 8.2% (190/2’311) among male and 6.0% (123/2’063) 
among female NHL patients, and was 2.6% (255/9’650) among female BC patients. 
In-hospital mortality of FN cases was 9.5% for men and 5.7% for women with NHL, 
and 4.3% for BC. Median inpatient treatment costs for an FN event were CHF 8’399 
(mean: CHF 14’006) in NHL and CHF 4’208 (mean: CHF 10’020) in BC. Nursing time was 
the most important cost component and length of stay was the most important driver 
of total inpatient cost. cOnclusiOns: 3% to 8% of all hospitalizations in NHL and 
BC patients were due to FN. Our results suggest that FN leads to considerable risk of 
death and incurs high in-hospital care cost in Switzerland.
PCN78
Cost assessmeNt of metastatIC aNd NoN-metastatIC CastratIoN-
resIstaNt Prostate CaNCer PatIeNt-maNagemeNt IN sPaIN
Morote J.1, Cozar J.M.2, Duran I.3, Gomez Veiga F.4, Leon L.5, Maroto P.6, Miñana B.7, Solsona E.8, 
Oyagüez I.9, Casado M.A.9, Roldán C.9, Gutierrez L.10, Hechmati G.11
1Vall d’Hebron Hospital. Universitat Autónoma de Barcelona, Barcelona, Spain, 2Hospital Virgen 
de las Nieves, Granada, Spain, 3Hospital Universitario Virgen del Rocío, Sevilla, Spain, 4CHUAC “A 
Coruña University Hospital, A Coruña, A Coruña, Spain, 5Hospital Clinico Universitario Santiago, 
Santiago de Compostela, Spain, 6Htal Sant Pau, Barcelona, Spain, 7Hospital Morales Meseguer, 
Murcia, Spain, 8I.V.O, Valencia, Spain, 9Pharmacoeconomics & Outcomes Research Iberia, Madrid, 
Spain, 10Amgen S.A., Barcelona, Spain, 11Amgen (Europe) GmbH, Zug, Switzerland
Objectives: To compare annual management costs of castration-resistant prostate 
cancer (CRPC) patients at high risk of developing bone metastases (BM) versus those 
that already had BM in Spain. MethOds: An expert panel of 5 urologists and 3 oncol-
ogists from Spanish health centres was asked to estimate the mean annual resource 
use in the management of non-metastatic CRPC patients and in the first, second and 
subsequent years after developing BM. Hospital resources were stratified into four 
major categories: 1) general resources [medical visits, diagnostic and monitoring pro-
cedures, hospital admission and surgeries], 2) hormone therapy, 3) chemotherapy and 
4) analgesic treatments. The last three categories included: drug costs, adverse event 
(AE) management-costs and pre-medication costs. Skeletal-related events (pathologi-
cal fracture, radiation or surgery to bone and spinal cord compression) often suffered 
by BM patients were excluded from the analysis as Spanish cost-related data had 
recently been published. Unit costs (€ , 2013) for each identified resource were obtained 
from a national cost-database. Results: Total management-related annual costs for 
non-metastatic CRPC patients were € 2,691.57; € 978.51 were hormone therapy drug 
costs, € 11.10 analgesics costs and € 243.55 AE management costs. No chemotherapy 
was administered in these patients. Annual management cost for BM patients was 
€ 6,000.37 the first year, € 14,468.35 the second year and € 14,313.87 in subsequent years. 
Hormone therapy drug costs accounted for € 946.67, € 948.13 and € 948.13 in the first, 
second and subsequent years, while chemotherapy costs accounted for € 1,892.21 
(32.2%); 9,485.41 (66.2%) and € 9,143.92 (64.4%), respectively. Analgesic costs increased 
from € 597.29 (first year) to € 915.16 and € 1,031.20 (second and subsequent years) and 
AE management costs increased from € 595.63 (first year) to € 758.58 (second year) 
and € 732.14 (subsequent years). cOnclusiOns: CRPC patients with BM had higher 
management costs than non-metastatic patients especially after the first year of 
treatment, which was mainly due to chemotherapy drug costs.
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Objectives: Little is known about costs of managing adverse events (AEs) associ-
ated with currently-available therapies in advanced melanoma. This study identi-
fies and estimates the costs of these AEs in France (FR), Italy (IT), The Netherlands 
(NL), and Spain (ES). MethOds: A comprehensive literature search was conducted 
to identify common grade 3/4 AEs from product labels and published phase II/III 
advanced melanoma studies in PubMed, conference abstracts, and European treat-
ment guidelines. Resource utilizations for the management of each type of AE in typ-
ical inpatient/outpatient treatment setting were determined via in-depth interviews 
with 5 melanoma clinicians in each country. Outpatient and inpatient 2012 costs 
were then estimated for each type of AE by applying country-specific tariffs, except 
in Spain where costs were obtained from government database or best published 
sources. Results: Most frequent grade 3/4 AEs associated with chemotherapies 
included neutropenia, vomiting, and anemia. Vemurafenib was commonly associ-
ated with cutaneous squamous cell carcinoma (CSCC)/keratoacanthoma, rash, and 
ment algorithms based on expert opinion. MethOds: This study uses the Delphi 
method to reach experts’ consensus on the clinical practices currently being used 
in Turkey. Delphi method has been widely used in medical areas where empirical 
data is scarce. The survey developed for this study includes questions to under-
stand the clinical resource use in order to calculate the associated costs. Although 
the panelists’ answers are unlikely to change after the second iteration accord-
ing to the literature, a three-iteration panel was needed to reach a consensus in 
practice. The consensus is then used to calculate the cost of an episode of care for 
genital warts (GW), CIN 1, CIN 2/3, different cervical cancer stages from the payer’s 
perspective. Results: TDP-HPV included a total of 10 experts, including gyneco-
oncologists, dermatologists and a medical oncologist. The cost of a GW episode of 
care is approximately USD 263.58 to the government. CIN 1 cases are only treated if 
the disease persists for 2 years, which happens in about 5% of cases. The cost of a 
CIN 1, CIN 2/3 episode of care is calculated as USD 127, USD 262 to the government, 
respectively. The cervical cancer (CC) stages are divided into local CC, regional CC, 
and distant CC. The costs associated with these states are USD 1,340, USD 4,345, 
and USD 8,150. cOnclusiOns: Early diagnosis and treatment is crucial from the 
cost perspective too as a more severe disease costs more. GWs are sometimes left 
out when HPV-related diseases are considered. However, this study mentions that 
GW presents a serious burden to the society.
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Objectives: EVE in association with aromatase inhibitor was recently approved 
by ANVISA (Brazilian Regulatory Agency) for MBC-HR+ patients. EVE redefines the 
role of endocrine therapy in MBC-HR+ reversing endocrine resistance. The aim of 
this study is to determine the costs associated to the introduction of EVE + EXE for 
the Brazilian private system population. MethOds: A previous study from real-
world (RW) data between 2011-12 (large private database of medical claims for 
chemotherapy (CT), Evidencias Database) and published data identified MBC-HR+ 
patients and evaluated costs of treatments and adverse events (AEs), by a micro-
costing approach. Patients were divided into three groups, according to metastasis: 
bone exclusive (B), Visceral exclusive (V) and Bone plus Visceral (BV). For this study 
the financial impact of the adoption of EVE+EXE was calculated in this population, 
based on the previous findings. Direct medical costs of EVE, hormones, CT, hospi-
talization, supportive care, radiation, monitoring and AEs were considered. A cohort 
of 100 patients with MBC-HR+ was simulated in a decision tree to obtain the costs 
for each group and the mean cost/ patient. Costs were estimated in 2013 Brazilian 
Real (R$). Results: RW data showed the following distribution of patients: B 38%, 
V 42% BV 20%. Lengths of treatment (months) were B 25.1-30, V 16.1; BV 14-19.6. 
Mean costs/patient/group, before EVE+EXE adoptions, were B R$135.744 (US$67,872), 
V R$129.079 (US$64,539) and BV R$117.172 (US$58,568). If EVE+EXE substituted 80% 
or 50% of the current treatments, the incremental percentage of costs would be B 
(5%; - 9%), V (5,7%; -16%) and BV (22%; 14%). Costs with AEs were at least 50% lower 
with the use of EVE+EXE. cOnclusiOns: EVE adoption in association with EXE 
may be cost saving for some groups of MBC-HR+ patients. For other groups, the 
incremental cost is not superior to 22%.
PCN75
estImated Costs of Her2-PosItIve metastatIC breast CaNCer for 
PatIeNts INItIatINg aN oral aNtICaNCer treatmeNt: results from a 
freNCH ProsPeCtIve observatIoNal study
Woronoff-Lemsi M.C.1, Chaix-Couturier C.2, Durand-Zaleski I.3, Espié M.4, Lortholary A.5, 
Merrouche Y.6, Flinois A.7, Chabernaud H.8, Benjamin L.9
1Department of Pharmacy, Besançon Cedex, France, 2Conseil Chaix-Couturier, Meudon, France, 
3Hôpital Henri Mondor, Créteil, France, 4Hôpital Saint Louis, Paris, France, 5Catherine de Sienne, 
Nantes, France, 6Institut de Cancérologie Lucien Neuwirth, Saint Priest en Jarez, France, 7Kantar 
Health, Paris, France, 8Kantar Health, Montrouge, France, 9GlaxoSmithKline, Marly le Roi, France
Objectives: To assess the cost of HER2-positive (HER2+) metastatic breast cancer 
(mBC) for patients initiating an oral anticancer treatment (OAT) from the perspective 
of the French National Health Insurance (NHI). MethOds:  A prospective observa-
tional multicenter study was conducted among 284 HER2+ mBC patients treated by 
68 oncologists initiating a treatment containing an OAT between March 2011 and 
February 2012. Costs data were available for 199 patients. Clinical characteristics, 
treatment patterns, quality-of-life, adherence and health care resources data were 
collected. Health care resource use data on hospitalization, medical consultation, 
drug and radiation-therapy were reported by oncologists at treatment initiation and 
after each 3-month period during a 9 months maximum period. Cost estimations 
were based on unit costs from national databases (French Diagnosis Related Group 
cost database and NHI database for drug unit cost). Results: A total of 109 patients 
(55%) received an OAT only and 90 (45%) received oral and intravenous (IV) drugs. 
Thirty patients (15%) were treated with radiation therapy and 43 patients (22%) 
with hormonal-therapy in addition to chemotherapy. The overall average cost of 
management per patient was 28,482€ ± 14,914 for all patients, 19,412€ ± 9,462 for 
patients with an OAT only and 39,467€ ± 12,770 for patients with oral and IV drugs. 
Drug costs were 27,669 € ± 14,976 and they represented 97% of the total hospital cost 
of management (hospitalizations, consultations and drugs). cOnclusiOns: This 
prospective observational study conducted among HER2+ mBC patients shows that 
the route of drug administration has an impact on treatment costs. Nevertheless, 
the study design does not allow concluding that OAT were associated with lower 
costs and cost savings. These finding however warrants further exploration within 
the context of micro-costing studies from the hospital and community perspective 
in order to better understand the health care resources used that are required to 
manage patients treated with OAT.
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Objectives: Prostate cancer (PCA) is the most common cancer in men worldwide. 
However, there is disagreement about the benefits of existing screening programs. 
This is mainly due to low specificity of currently utilized biomarkers. This can lead 
to both inappropriate medical treatment and increasing costs of care. For the future, 
many biotechnological developments are promising, but not all will be affordable 
for routine screening. The question is how much a complementary biomarker to 
prostate-specific antigen (PSA)-test may cost which would be applied to avoid false-
positive results. MethOds: Conduct of a hybrid discrete-event and system-dynamics 
simulation by applying AnyLogic. Based on clinical guidelines and expert knowl-
edge, a hypothetical PCA screening workflow was developed and supplemented by 
a proposed innovative biomarker. Demographic and patient behavior information, 
disease related data on incidence as well as sensitivity and specificity of PSA, digital-
rectal examination and prostate biopsy were further implemented in the model. 
Economic consequences were calculated by considering costs for examinations, 
biopsy diagnosis and complications. Results: In Germany, annual screening would 
be recommended for 18.8 million men aged ≥ 45 years. Assuming a biomarker speci-
ficity of 80%, approximately 70% of prostate biopsies could be avoided. This could 
lead to a reduction of biopsy caused complications. Regarding the latter, mean costs 
of 204.17€ were calculated. Due to prevented check-ups and biopsy-complications, 
cost neutrality for the supposed biomarker will be reached when applying a price 
of 48.50€ . cOnclusiOns: A complementary biomarker could lead to more precise 
diagnosis and additional value for patients and health insurance funds. Although the 
price may not be high, an implementation may nevertheless be feasible for companies 
due to the high number of examinations. Funded by the German Federal Ministry of 
Education and Research (BMBF) as part of the National Cluster of Excellence Medical 
Technology - Medical Valley EMN (Project grant No. 01EX1013B).
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Objectives: To estimate the cost of diagnostic investigation and treatment 
for breast cancer in an Irish teaching hospital from a health payer perspec-
tive. MethOds: Retrospective population based resource utilisation data for n=611 
patients treated for primary breast cancer in a university teaching hospital in Ireland 
were available for the period 2009-2011. Health care resource use included diagnostic 
investigations and all treatments. Unit costs for diagnosis & surgical procedures, 
laboratory tests, and radiotherapy were derived from DRG costs, hospital finance 
departments, clinical opinion and literature review. Chemotherapy costs were esti-
mated from local hospital protocols, pharmacy departments and clinical opinion. 
Associated pharmaceutical cost, including oral hormonal therapy, were estimated 
from the HSE Primary Care Reimbursement Services claims database. Overall and 
mean costs by stage of breast cancer are presented with bootstrap 95% confidence 
intervals (CIs). Results: Total cost of diagnosis, treatment and follow-up was 
estimated at €15.2 million over the 3 year period, with an average cost of €24,863 
per patient (95% CI; €22,628, €27,197). Chemotherapy and other pharmaceuticals 
accounted for 47%, radiotherapy 19%, surgery 19%, diagnostics 5%, radiology 2% and 
follow-up 8% of total expenditure. The biological agent trastuzumab accounted for 
43% of total pharmaceutical expenditure. Costs varied by stage at diagnosis. The 
average cost per patient by stage at diagnosis was estimated as follows; Stage 1 (n 
= 186) €23,821 (95% CI; €20,113, €27,846); Stage 2 (n=248) €24,919 (95% CI; €21,358, 
€28,626); Stage 3 (n=121) €30,172 (95% CI; €25,434, €35,366); Stage 4 (n=56) €16,570 
(95% CI; €7,964, €25,836). cOnclusiOns: This study demonstrates the value of using 
existing data from national and local databases in estimating the cost of diagnosis 
and management of breast cancer from a health payer perspective and highlights 
the impact of trastuzumab on overall costs.
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Objectives: To estimate the frequency and costs of hospital stays for cancer 
patients receiving cytotoxic chemotherapies inducing febrile neutropenia (FN), in 
public and private hospitals in France. MethOds: The French Hospital National 
Database (PMSI) is a comprehensive claims database which includes information 
on diagnoses an procedures and allows record linkage. Hospital stays for patients 
admitted with hematologic or solid tumors in 2010/2011 were extracted and an ad 
hocalgorithm selected those for which the primary admission reason was FN, as well 
as those due to an infectious syndrome resulting from FN. Economic valuations were 
based on 2010 public national tariffs and National Scale Costs (ENCC). Results: 
A total of 14,685 hospital stays were analyzed (3,776 stays for the treatment of 
hematologic tumors and 10,909 for solid tumors) corresponding to 10,721 patients 
treated for FN (2,386 patients first treated for hematologic tumor and 8,343 first 
treated for solid tumor). The proportions of patients hospitalized for FN were 12.2% 
for hematologic tumors and 7.0% for solid tumors. The average length of stay was 
7 days for patients with hematologic tumors and 6.5 days for patients with solid 
tumors. In the sub analysis, non-Hodgkin’s lymphoma (11.7%) and lung cancer 
(11.8%) were, respectively, the most common hematologic and solid tumor types 
in patients hospitalized for FN. The mean costs of treatments associated with FN 
per patient were 7,820.67€ for hematologic tumors, 4,907.83€ for solid tumors and, 
in the sub-analysis, 6,816€ for non-Hodgkin’s lymphoma and 4,907€ for lung can-
cer. cOnclusiOns: The PMSI is a useful source to estimate the treatment costs 
associated with FN in France. In 2010/2011, febrile neutropenia induced a total of 
14,685 stays and a total cost of 59.6 million euros for the Statutory Health Insurance.
elevated liver enzymes, while dabrafenib was most often associated with CSCC 
and pyrexia. The most common AEs associated with trametinib were hyperten-
sion and rash. Common ipilimumab AEs were immune-related diarrhea/colitis, 
dyspnea, anemia, vomiting, and less frequently, hypophysitis. In the outpatient 
setting, the most costly AEs per incident included anemia (€ 1,431, € 1,309, € 1,276; 
ES, IT, FR) and CSCC (€ 1,058; NL). Other costly outpatient treatments include those 
for hypophysitis (€ 463, € 449, € 321; NL, ES, IT), febrile neutropenia (€ 593, € 430; IT, 
ES), and CSCC (€ 483, € 292; ES, IT). In the inpatient setting, the most costly AEs per 
hospitalization per country were hypophysitis (€ 10,189; ES), elevated liver enzymes 
(€ 6,868; FR), anemia (€ 2,826, € 2,628; NL, IT). Additional inpatient treatments with 
high costs were diarrhea (€ 4,083; ES), neutropenia (€ 2,322; IT) and vomiting (€ 2,036; 
NL). cOnclusiOns: Costs of managing AEs can be substantial, and effective new 
treatments with reduced AE profiles would be valuable.
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Objectives: Squamous cell carcinoma of the anus (SCCA) generally requires a 
number of complex interventions as part of a multidisciplinary approach to treat-
ment. This research aimed to combine available data on disease progression 
and treatment in order to estimate the average cost of treating a case of SCCA in 
England. MethOds: Data on primary treatment, disease progression and follow-up 
were obtained from the Association of Coloproctology of Great Britain and Ireland’s 
anal cancer position statement, supplemented by expert opinion where necessary. 
First, decision trees were constructed to estimate the costs of diagnosis, staging 
and primary treatment. A Markov model was then developed to simulate disease 
progression and follow-up based on the mode of primary treatment (combined 
modality therapy versus radiotherapy alone). Values for unknown parameters were 
jointly selected from within plausible ranges and model outputs for each simula-
tion were then compared to empirical data on overall mortality and locoregional 
relapse. Goodness of fit was estimated using ordinary least squares. All costs applied 
to treatments and interventions were taken from the 2010/11 National Tariff, with 
the 2010/11 Reference Costs used for off tariff payments. A one-way sensitivity 
analysis was also performed. Results: The cost of treating a case of SCCA was 
estimated to be in the range of £16,448-£16,630 when future inflation was taken into 
account, and £16,278-£16,455 when it was not. In the one-way sensitivity analysis, 
the adjusted value ranged between £14,309-£23,264 (unadjusted £14,139-£23,077), 
with the results most sensitive to changes in the mode of admission for primary 
treatment and the costs of staging/diagnosis. cOnclusiOns: Despite limitations 
in the approach resulting from a lack of available data, these results indicate that 
the cost of treating SCCA is significant. Further observational work is required in 
order to verify these findings.
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Objectives: Information on the costs of managing adverse events (AEs) associated 
with currently-available treatment regimens in advanced melanoma is limited. This 
study identifies treatment-related AEs associated with commonly-used regimens 
recommended in US guidelines, and estimates the costs of treating these AEs in 
the US. MethOds: Grade 3 and 4 AEs were identified by a comprehensive litera-
ture search of product labels and published English-language phase II/III advanced 
melanoma studies in PubMed, conference abstracts, and NCCN guidelines. In-depth 
interviews with 5 US melanoma clinicians were performed to obtain resource uti-
lization and treatment setting information for managing each type of AE. Costs 
(2012$) were then estimated for each type of AE in outpatient and inpatient settings, 
using Medicare reimbursement rates for the outpatient setting, and Healthcare 
Utilization Project estimates for the inpatient setting. Results: The most common 
grade 3 and 4 AEs associated with chemotherapy regimens included neutropenia, 
vomiting, and anemia. Cutaneous squamous cell carcinoma (CSCC)/keratoacan-
thoma, rash, and elevated liver enzymes were most common AEs associated with 
vemurafenib, while CSCC and pyrexia were most often associated with dabrafenib. 
The most common AEs associated with trametinib were hypertension and rash. 
Common ipilimumab AEs included immune-related diarrhea/colitis, dyspnea, ane-
mia, and vomiting, and less frequent hypophysitis. The highest cost per incident 
in the outpatient setting among these AEs was neutropenia ($2,039), followed by 
CSCC ($369), vomiting ($342), and dyspnea ($222). The highest costs per hospitaliza-
tion were for CSCC ($18,906), followed by hypophysitis ($15,721) and febrile/afebrile 
neutropenia ($11,125). Other costly AEs in the inpatient setting include hypertension 
($8,113), diarrhea ($6,881), dyspnea ($6,826), vomiting ($6,046), anemia ($6,014), and 
elevated liver enzymes ($5,942). All hospitalizations due to AEs were more than 
$4,000 per incident. cOnclusiOns: The costs of managing treatment-related AEs 
in advanced melanoma are considerable, and there is need for effective treatments 
with improved toxicity profiles.
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